ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reaffirmed by investment analysts at Beaufort Securities in a report released on Thursday. They currently have a GBX 6.50 ($0.09) price objective on the stock.

Shares of ValiRx Plc (LON VAL) traded down GBX 0.07 ($0.00) during trading on Thursday, hitting GBX 0.93 ($0.01). The stock had a trading volume of 3,818,142 shares, compared to its average volume of 2,050,000. ValiRx Plc has a 12-month low of GBX 0.90 ($0.01) and a 12-month high of GBX 7.24 ($0.10).

WARNING: This piece of content was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with Analyst Ratings Network's FREE daily email newsletter.